U.S. District Judge M. Casey Rodgers, in the Northern District of Florida, postponed her expert ruling this month due to a ...

Things are going from bad to worse for the pharmaceutical giant.

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its cl ...

(NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE ® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the ...

The decision was based on results published earlier this year from the Phase III PATINA trial, but median progression-free survival analysis remains fuzzy.

Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Integrin β6 is expressed in ~90% of NSCLC and correlates with poor prognosis, supporting development of a selective, rapidly internalizing ADC designed to reduce off-target integrin binding.

Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of ...